论文部分内容阅读
目的:观察二甲双胍对代谢综合征(MS)的干预效果及可能机制。方法:将124例MS患者随机分为两组,生活方式干预组仅行生活方式干预,二甲双胍组在此基上加服二甲双胍,干预前及干预后半年分别测量体重指数(BMI)、收缩压和舒张压(SBP、DBP)、空腹血糖(FBG)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、血浆脂联素水平(APN)、空腹胰岛素(FINS),并计算胰岛素敏感性指数(ISI)等。结果:治疗后两组SBP、DBP、TG均较干预前明显下降(P<0.01),两组间无明显差异(P>0.05);二甲双胍组BMI、FBG、FINS较前明显下降,APN、ISI较前明显升高(P<0.01),而生活方式干预组上述指标的变化不明显(P>0.05),两组比较有显著性差异(P<0.01、P<0.05)。结论:非糖尿病MS患者口服二甲双胍半年后APN水平和ISI明显升高,MS 5项指标均明显改善。
Objective: To observe the effect of metformin on metabolic syndrome (MS) and its possible mechanism. Methods: A total of 124 patients with MS were randomly divided into two groups. Life style intervention group was given only lifestyle intervention. Metformin group was given metformin on this basis. Body mass index (BMI), systolic blood pressure DBP, FBG, TG, HDL-C, APN, FINS were calculated and insulin was calculated Sensitivity Index (ISI) and so on. Results: After treatment, SBP, DBP and TG in both groups were significantly lower than those before intervention (P <0.01), there was no significant difference between the two groups (P> 0.05); BMI, FBG and FINS in metformin group were significantly lower than before, (P <0.01), while those in lifestyle intervention group did not change significantly (P> 0.05). There was significant difference between the two groups (P <0.01, P <0.05). CONCLUSIONS: APN and ISI were significantly elevated in metformin six months after oral administration of metformin in non-diabetic MS patients, with significant improvement in all five MS indicators.